Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benzydamine + oxolamine citrate is a fixed-dose combination therapy used for the symptomatic treatment of inflammatory conditions of the mouth and throat, as well as associated respiratory symptoms such as cough. Benzydamine is a locally-acting non-steroidal anti-inflammatory drug (NSAID) that possesses analgesic, antipyretic, and local anesthetic properties; it works primarily by inhibiting the production of pro-inflammatory cytokines like TNF-alpha and IL-1beta. Oxolamine citrate is a peripheral antitussive and anti-inflammatory agent that reduces the sensitivity of cough receptors in the respiratory tract and helps alleviate bronchial irritation. Developed by Angelini and marketed by Sam-A Pharmaceutical in South Korea under brand names such as Pebron and Tantum, this combination is typically formulated as a syrup or oral solution for the relief of pharyngitis, tonsillitis, and tracheobronchitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benzydamine + oxolamine citrate.